Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
January 04 2022 - 8:00AM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage
company developing transformative therapies for the treatment of
cancer and rare diseases with significant unmet needs, today
announced that management will present at the H.C. Wainwright
BioConnect Virtual Conference being held from January 10-13, 2022.
The prerecorded presentation will become
available on Monday, January 10, 2022 at 7:00am ET and can be
accessed by visiting the Events and Presentations section of the
Company’s website: https://ir.protaratx.com. The webcast will be
archived on the Company’s website for 90 days following the
presentation.
About Protara
Therapeutics, Inc.Protara is committed to
identifying and advancing transformative therapies for people with
cancer and rare diseases with limited treatment options. Protara’s
portfolio includes its lead program, TARA-002, an investigational
cell-based therapy being developed for the treatment of non-muscle
invasive bladder cancer and lymphatic malformations, and IV Choline
Chloride, an investigational phospholipid substrate replacement
therapy for the treatment of intestinal failure-associated liver
disease. For more information, visit www.protaratx.com.
Company Contact:Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024